Antiplatelet and antioxidant drugs for dry AMD with drusen
Treatments studied
Part of Eyes & vision clinical trials.
This study tests whether antiplatelet drugs (like aspirin) and antioxidants can slow the growth of drusen (yellow deposits) in dry age-related macular degeneration (AMD). It may help prevent the disease from worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have dry age-related macular degeneration (AMD) with at least one large drusen (a yellowish deposit larger than 125 microns).
- You have taken antiplatelet drugs (like aspirin or clopidogrel) in the past.
- You do not have advanced AMD (like geographic atrophy or wet AMD) or other retinal diseases (like retinal detachment or diabetic macular edema).
- You have not had a prior injection of anti-VEGF (a drug for wet AMD) or laser treatment in the eye.
- You are not currently taking certain medications like SSRIs, SNRIs, azole antifungals, NSAIDs, more than one antiplatelet drug, or blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how dry age-related macular degeneration (AMD) changes over time using regular eye exams. It may help doctors better understand the natural pattern of progression and which patients are more likely to worsen.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.